NCT03095807

Investigation of Single Ascending Doses of NNC9204-1706 in Male Subjects Being Overweight or With Obesity

Investigation on Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of NNC9204-1706 in Male Subjects Being Overweight or With Obesity

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 34 (actual)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: Male
• Age: 18 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

This trial is conducted in the United States of America (USA). The aim of this trial is to assess the safety and tolerability of single doses of NNC9204-1706 administered subcutaneously in male subjects being overweight or with obesity.

Conditions

• Metabolism and Nutrition Disorder
• Obesity

Interventions

Type	Name	Description
DRUG	NNC9204-1706 A	Administered subcutaneously (s.c., under the skin) Up to 7 dose cohorts will be investigated.
DRUG	Placebo	Administered subcutaneously (s.c., under the skin)

Timeline

• Start date: 2017-03-20
• Primary completion: 2017-08-31
• Completion: 2017-08-31
• First posted: 2017-03-30
• Last updated: 2018-10-05

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study